MergerLinks Daily Review

Welcome to MergerLinks Daily Review.?Sign up here ?to get the full round up of your daily dose of blue-chip M&A news directly to your inbox.

Takeda completed the acquisition of Nimbus Lakshmi for $6bn.

Globus Medical to merge with NuVasive in a $3.1bn deal.

Post Holdings to acquire pet food brands of The J.M. Smucker Co for $1.2bn.

Thailand’s AIS weighs options for $3bn tower assets.

First Abu Dhabi Bank could renew $35bn offer for StanChart.

You can access today’s complete newsletter?here.

Scroll down for more…

Takeda completed the acquisition of Nimbus Lakshmi for $6bn.

Takeda , a pharmaceutical company, completed the acquisition of Nimbus Lakshmi, a wholly-owned subsidiary of Nimbus Therapeutics , a developer of small molecule compounds, for $6bn.

"We are thrilled to reach this important milestone for what we believe is a best-in-class molecule in the new therapeutic class of oral, selective allosteric TYK2 inhibitors, which has the potential to address high unmet need for patients across a broad range of immune-mediated diseases. We look forward to continuing to design future breakthrough medicines, leveraging Nimbus' unique approach at the intersection of computational chemistry and pharmaceutical sciences, and building on our track record of success." Jeb Keiper, Nimbus CEO.

Takeda was advised by Evercore (led by? Francois Maisonrouge ) and Cleary Gottlieb Steen & Hamilton LLP (led by? Kimberly Spoerri ). Nimbus was advised by J.P. 摩根 (led by? Ben Carpenter ), Goodwin (led by? Bill Collins ,? Sarah A. Solomon ?and?Erini Svokos) and Ten Bridge Communications .

Globus Medical to merge with NuVasive in a $3.1bn deal.

Globus Medical , a musculoskeletal solutions company, agreed to merge with NuVasive , a medical devices company based in San Diego, in a $3.1bn deal.

"This transaction reflects our mission to become the leading musculoskeletal technology company in the world by developing products that promote healing in patients with musculoskeletal disorders. With NuVasive, we can help support more patients through leading innovation and expanding our commercial reach to provide superior service to our surgeon and hospital partners. We look forward to combining the NuVasive and Globus Medical teams to capitalize on the many opportunities to improve patient care and create sustainable shareholder value," Dan Scavilla, Globus Medical President and CEO.

NuVasive is advised by 美国银行 and Wachtell, Lipton, Rosen & Katz . Globus Medical is advised by 高盛 and Goodwin .

Post Holdings to acquire pet food brands of The J.M. Smucker Co for $1.2bn.

Post Holdings , a consumer packaged goods holding company, agreed to acquire pet food brands of The J.M. Smucker Co. , an American manufacturer of food and beverage products, for $1.2bn.

"We expect this acquisition to continue our history of creating value with a buy and build approach to categories. These iconic brands are ideally suited to this strategy. Most importantly, I am delighted to welcome the over 1k talented people who will join us as Post colleagues," Rob Vitale, Post President and CEO.

The J.M. Smucker Co is advised by 高盛 and Wachtell, Lipton, Rosen & Katz (led by? Steven Rosenblum ?and? Ron Chen ). Post Holdings is advised by Barclays and Evercore .

Thailand’s AIS weighs options for $3bn tower assets.?

AIS , Thailand’s biggest telecommunications group, is considering options for its tower business including a stake sale,?Bloomberg ?reported.

The Bangkok-listed company has held talks with potential advisers for a strategic review for the assets. Another option under consideration is creating an infrastructure fund for the assets that could be listed on the Bangkok stock exchange.

First Abu Dhabi Bank could renew $35bn offer for StanChart.?

First Abu Dhabi Bank (FAB) , the United Arab Emirates’ biggest lender, could renew a potential offer for Britain’s 渣打银行 , once lock-up rules from its previous aborted bid expire.

StanChart shares rose as much as 9% on the news report. The Abu Dhabi lender is considering reviving the bid once a lock-up period that prevents it immediately doing so expires, offering $30bn to $35bn compared with StanChart’s market value of $24bn,?Reuters ?reported.

Interested to find more??Sign up here ?to get full round up of your daily dose of blue-chip M&A news directly to your inbox.

You can access today’s complete newsletter here.